CoChat

Machine learning approaches for drug combination therapies

Güvenç Paltun, Betül, Kaski, Samuel, Mamitsuka, Hiroshi · 2021 · Briefings in Bioinformatics
Cited by 87

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Drug combination therapy is a promising strategy to treat complex diseases such as cancer and infectious diseases. However, current knowledge of drug combination therapies, especially in cancer patients, is limited because of adverse drug effects, toxicity and cell line heterogeneity. Screening new drug combinations requires substantial efforts since considering all possible combinations between drugs is infeasible and expensive. Therefore, building computational approaches, particularly machine learning methods, could provide an effective strategy to overcome drug resistance and improve therapeutic efficacy. In this review, we group the state-of-the-art machine learning approaches to analyze personalized drug combination therapies into three categories and discuss each method in each category. We also present a short description of relevant databases used as a benchmark in drug combination therapies and provide a list of well-known, publicly available interactive data analysis portals. We highlight the importance of data integration on the identification of drug combinations. Finally, we address the advantages of combining multiple data sources on drug combination analysis by showing an experimental comparison.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bib/bbab293

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 59

  1. Pemovska, 2018, Recent advances in combinatorial drug screening and synergy scoring, Curr Opin Pharmacol, 42, 102, 10.1016/j.coph.2018.07.008 · DOI
  2. Lopez, 2017, Combine and conquer: challenges for targeted therapy combinations in early phase trials, Nat Rev Clin Oncol, 14, 57, 10.1038/nrclinonc.2016.96 · DOI · Paper page
  3. Ryall, 2015, Systems biology approaches for advancing the discovery of effective drug combinations, J Chem, 7, 1
  4. Bulusu, 2016, Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives, Drug Discov Today, 21, 225, 10.1016/j.drudis.2015.09.003 · DOI · Paper page
  5. Sheng, 2018, Advances in computational approaches in identifying synergistic drug combinations, Brief Bioinform, 19, 1172
  6. Madani Tonekaboni, 2018, Predictive approaches for drug combination discovery in cancer, Brief Bioinform, 19, 263, 10.1093/bib/bbw104 · DOI · Paper page
  7. Hasselt, 2019, Systems pharmacology: defining the interactions of drug combinations, Annu Rev Pharmacol Toxicol, 59, 21, 10.1146/annurev-pharmtox-010818-021511 · DOI
  8. Tsigelny, 2019, Artificial intelligence in drug combination therapy, Brief Bioinform, 20, 1434, 10.1093/bib/bby004 · DOI · Paper page
  9. Jia, 2009, Mechanisms of drug combinations: interaction and network perspectives, Nat Rev Drug Discov, 8, 111, 10.1038/nrd2683 · DOI · Paper page
  10. Liu, 2018, Anti-cancer drug response prediction using neighbor-based collaborative filtering with global effect removal, Mol Ther Nucleic Acids, 13, 303, 10.1016/j.omtn.2018.09.011 · DOI
  11. Güvenç Paltun, 2021, Diverse: Bayesian data integrative learning for precise drug response prediction, IEEE/ACM Trans Comput Biol Bioinform, 1, 10.1109/TCBB.2021.3065535 · DOI
  12. Tang, 2013, Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways, PLoS Comput Biol, 9, 10.1371/journal.pcbi.1003226 · DOI · Paper page
  13. Tang, 2014, Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles, Curr Pharm Des, 20, 23, 10.2174/13816128113199990470 · DOI · Paper page
  14. Jaeger, 2017, Quantification of pathway cross-talk reveals novel synergistic drug combinations for breast cancer, Cancer Res, 77, 459, 10.1158/0008-5472.CAN-16-0097 · DOI · Paper page
  15. Saputra, 2018, Combination therapy and the evolution of resistance: the theoretical merits of synergism and antagonism in cancer, Cancer Res, 78, 2419, 10.1158/0008-5472.CAN-17-1201 · DOI
  16. Ianevski, 2020, Syntoxprofiler: an interactive analysis of drug combination synergy, toxicity and efficacy, PLoS Comput Biol, 16, 10.1371/journal.pcbi.1007604 · DOI · Paper page
  17. Tang, 2015, What is synergy? The Saariselkä agreement revisited, Front Pharmacol, 6, 181, 10.3389/fphar.2015.00181 · DOI · Paper page
  18. Gayvert, 2017, A computational approach for identifying synergistic drug combinations, PLoS Comput Biol, 13, 10.1371/journal.pcbi.1005308 · DOI · Paper page
  19. Doroshow, 2017, On the design of combination cancer therapy, Cell, 171, 1476, 10.1016/j.cell.2017.11.035 · DOI
  20. Scott, 2020, Dolutegravir/lamivudine single-tablet regimen: a review in HIV-1 infection, Drugs, 80, 61, 10.1007/s40265-019-01247-1 · DOI
  21. Spain, 2016, Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations, Expert Opin Pharmacother, 17, 1031, 10.1517/14656566.2016.1168805 · DOI
  22. Iwata, 2015, Large-scale prediction of beneficial drug combinations using drug efficacy and target profiles, J Chem Inf Model, 55, 2705, 10.1021/acs.jcim.5b00444 · DOI
  23. Zhao, 2013, Systems pharmacology of adverse event mitigation by drug combinations, Sci Transl Med, 5, 10.1126/scitranslmed.3006548 · DOI · Paper page
  24. Das, 2018, A survey of the structures of US FDA approved combination drugs, J Med Chem, 62, 4265, 10.1021/acs.jmedchem.8b01610 · DOI · Paper page
  25. Liu, 2010, DCDB: drug combination database, Bioinformatics, 26, 587, 10.1093/bioinformatics/btp697 · DOI · Paper page
  26. Hare, 1990, The Orange Book: the Food and Drug Administration’s advice on therapeutic equivalence, Am Pharm, 35–37
  27. Menden, 2019, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat Commun, 10, 1, 10.1038/s41467-019-09799-2 · DOI · Paper page
  28. Chen, 2014, ASDCD: antifungal synergistic drug combination database, PloS one, 9, 10.1371/journal.pone.0086499 · DOI · Paper page
  29. Preuer, 2018, DeepSynergy: predicting anti-cancer drug synergy with deep learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
  30. Guo, 2021, Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients, Nucleic Acids Res, 49, e37, 10.1093/nar/gkaa1272 · DOI
  31. Julkunen, 2020, comboFM: leveraging multi-way interactions for systematic prediction of drug combination effects, bioRxiv
  32. Di Veroli, 2016, Combenefit: an interactive platform for the analysis and visualization of drug combinations, Bioinformatics, 32, 2866, 10.1093/bioinformatics/btw230 · DOI · Paper page
  33. Ianevski, 2017, SynergyFinder: a web application for analyzing drug combination dose–response matrix data, Bioinformatics, 33, 2413, 10.1093/bioinformatics/btx162 · DOI · Paper page
  34. Güvenç Paltun, 2021, Improving drug response prediction by integrating multiple data sources: matrix factorization, kernel and network-based approaches, Brief Bioinform, 22, 346, 10.1093/bib/bbz153 · DOI
  35. Xia, 2018, Predicting tumor cell line response to drug pairs with deep learning, BMC Bioinformatics, 19, 71
  36. Zagidullin, 2019, DrugComb: an integrative cancer drug combination data portal, Nucleic Acids Res, 47, W43, 10.1093/nar/gkz337 · DOI · Paper page
  37. Huang, 2014, DrugComboRanker: drug combination discovery based on target network analysis, Bioinformatics, 30, i228, 10.1093/bioinformatics/btu278 · DOI · Paper page
  38. Jeon, 2018, In silico drug combination discovery for personalized cancer therapy, BMC Syst Biol, 12
  39. Ianevski, 2019, Prediction of drug combination effects with a minimal set of experiments, Nat Mach Intell, 1, 568, 10.1038/s42256-019-0122-4 · DOI · Paper page
  40. Zhao, 2011, Prediction of drug combinations by integrating molecular and pharmacological data, PLoS Comput Biol, 7, 10.1371/journal.pcbi.1002323 · DOI · Paper page
  41. Li, 2015, Large-scale exploration and analysis of drug combinations, Bioinformatics, 31, 2007, 10.1093/bioinformatics/btv080 · DOI · Paper page
  42. Chen, 2016, NLLSS: predicting synergistic drug combinations based on semi-supervised learning, PLoS Comput Biol, 12, 10.1371/journal.pcbi.1004975 · DOI · Paper page
  43. Li, 2017, Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles, Artif Intell Med, 83, 35, 10.1016/j.artmed.2017.05.008 · DOI
  44. Held, 2013, Genotype-selective combination therapies for melanoma identified by high-throughput drug screening, Cancer Discov, 3, 52, 10.1158/2159-8290.CD-12-0408 · DOI · Paper page
  45. Liu, 2019, Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network, BMC Bioinformatics, 20, 1, 10.1186/s12859-019-3288-1 · DOI · Paper page
  46. Karimi, 2020, Network-principled deep generative models for designing drug combinations as graph sets, Bioinformatics, 36, i445, 10.1093/bioinformatics/btaa317 · DOI
  47. Sun, 2020, DTF: Deep tensor factorization for predicting anticancer drug synergy, Bioinformatics, 36, 4483, 10.1093/bioinformatics/btaa287 · DOI
  48. Kuhn, 2010, STITCH 2: an interaction network database for small molecules and proteins, Nucleic Acids Res, 38, D552, 10.1093/nar/gkp937 · DOI · Paper page
  49. Chen, 2002, Therapeutic target database, Nucleic Acids Res, 30, 412, 10.1093/nar/30.1.412 · DOI · Paper page
  50. Hamosh, 2005, Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders, Nucleic Acids Res, 33, D514
  51. Kanehisa, 2007, KEGG for linking genomes to life and the environment, Nucleic Acids Res, 36, D480, 10.1093/nar/gkm882 · DOI · Paper page
  52. Liu, 2007, BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities, Nucleic Acids Res, 35, D198, 10.1093/nar/gkl999 · DOI · Paper page
  53. Roth, 2000, The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?, Neuroscientist, 6, 252, 10.1177/107385840000600408 · DOI · Paper page
  54. Zhu, 2010, Update of TTD: therapeutic target database, Nucleic Acids Res, 38, D787, 10.1093/nar/gkp1014 · DOI · Paper page
  55. Forcina, 2017, Systematic quantification of population cell death kinetics in mammalian cells, Cell Systems, 4, 600, 10.1016/j.cels.2017.05.002 · DOI · Paper page
  56. Licciardello, 2017, A combinatorial screen of the cloud uncovers a synergy targeting the androgen receptor, Nat Chem Biol, 13, 771, 10.1038/nchembio.2382 · DOI
  57. Griner, 2014, High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells, Proc Natl Acad Sci, 111, 2349, 10.1073/pnas.1311846111 · DOI · Paper page
  58. Sun, 2016, Drug combination therapy increases successful drug repositioning, Drug Discov Today, 21, 1189, 10.1016/j.drudis.2016.05.015 · DOI · Paper page
  59. Liu, 2020, DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy, Nucleic Acids Res, 48, D871

Cited by

See all 87

Metadata

Authors
Güvenç Paltun, B., Kaski, S., & Mamitsuka, H.
Venue
Briefings in Bioinformatics
Published
2021-08-06
Volume
22
Issue
6
ISSN
  • 1467-5463
  • 1477-4054
Cited by
87
References
20
Language
en
Funders
  • JST ACCEL (JPMJAC1503)
  • MEXT Kakenhi (16H02868, 19H04169)
  • Academy of Finland (315896)
  • Finnish Center for Artificial Intelligence FCAI (320181)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Machine learning approaches for drug combination therapies. https://app.cochat.ai/papers/10.1093/bib/bbab293
The paper
Güvenç Paltun, B., Kaski, S., & Mamitsuka, H. (2021). Machine learning approaches for drug combination therapies. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbab293

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.